High expression of the bile salt‐homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis

@article{Schaap2009HighEO,
  title={High expression of the bile salt‐homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis},
  author={Frank G. Schaap and Niels A van der Gaag and Dirk Joan Gouma and Peter L. M. Jansen},
  journal={Hepatology},
  year={2009},
  volume={49}
}
Fibroblast growth factor 19 (FGF19) is an endocrine factor produced by the small intestine in response to uptake of luminal bile salts. In the liver, FGF19 binds to FGF receptor‐4, resulting in down‐regulation of cytochrome P (CYP) 7A1 and reduced bile salt synthesis. Down‐regulation of CYP7A1 under cholestatic conditions has been attributed to bile salt–mediated induction of the transcriptional repressor short heterodimer partner (SHP), because the interrupted enterohepatic cycle of bile salts… 
Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.
TLDR
New findings showed that targeting bile acid metabolism and signaling may be promising therapeutic approaches for treating ALD.
The portal‐drained viscera release fibroblast growth factor 19 in humans
TLDR
FGF19 levels in human portal blood are higher than in arterial blood, and FGF19 is released by the portal‐drained viscera under fasted steady state conditions.
Fibroblast Growth Factor 19 Activates the Unfolded Protein Response and Mitogen-Activated Protein Kinase Phosphorylation in H-69 Cholangiocyte Cells.
TLDR
It is speculated that FGF19 has an important role in the pathogenesis of many human cholangiopathies and cholestatic liver disorders.
Profiling Circulating and Urinary Bile Acids in Patients with Biliary Obstruction before and after Biliary Stenting
TLDR
It is demonstrated that biliary obstruction affects differentially the circulating and/or urinary levels of the various bile acids, and the observation that the most drastically affected acids correspond to the less toxic species supports the activation of self-protecting mechanisms aimed at limiting the inherent toxicity of biliary acids in face of bile obstruction.
Regulation of hepatic ABCC transporters by xenobiotics and in disease states
TLDR
The regulation of hepatic ABCC transporters in humans and rodents by a variety of xenobiotics, under disease states and in genetically modified animal models deficient in transcription factors, transporter, and cell-signaling molecules is described.
The ascending pathophysiology of cholestatic liver disease
TLDR
It is developed and proposed a new view on the pathophysiology of primary biliary cholangitis and PSC in the hope that these new drugs can be used more effectively, and anti‐inflammatory agents are probably most effective in early disease, while drugs that antagonize BS toxicity may be effective at all disease stages.
The human gallbladder secretes fibroblast growth factor 19 into bile: Towards defining the role of fibroblast growth factor 19 in the enterobiliary tract
TLDR
The combined findings raise the intriguing possibility that biliary FGF19 has a signaling function in the biliary tract that differs from its established signalingfunction in the portal circulation.
The role of fibroblast growth factor 19 in human liver
TLDR
Physiological levels of FGF19 are established and an adaptive response of the liver to increased hepatic bile acids and an interrupted enterohepatic circulation was observed at time of surgery, with reduced bile acid synthesis, increased levels of circulating biles acids and alterations in bile Acid transporters, indicating that FGF 19 could be a possible prognostic marker for outcome of KPE in biliary atresia.
Evaluation of FGF-19 and β-klotho as biomarkers in patients with intrahepatic cholestasis of pregnancy
TLDR
In some cases, abnormalities in the FGF-19, β-klotho, and FGFR4 signaling system may play roles in the pathogenesis of ICP, however, in some cases the abnormalities do not differ between the pregnancies with ICP and the healthy controls.
Bile Acid Signaling in Metabolic Disease and Drug Therapy
TLDR
An interaction of liver bile acids and gut microbiota in the regulation of liver metabolism and potential therapeutic agents for treating metabolic diseases of the liver are revealed.
...
...

References

SHOWING 1-10 OF 27 REFERENCES
Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTα-OSTβ in cholestasis in humans and rodents
Organic solute transporter (OSTα-OSTβ) is a novel heteromeric bile acid and sterol transporter expressed at the basolateral membranes of epithelium in the ileum, kidney, and liver. To determine whe...
Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis
TLDR
The transcriptional regulation of bile acid transporting proteins and metabolizing enzymes mediated by nuclear hormone receptors is provided, with implications of targeting these receptors for the treatment of cholestasis are discussed.
Liver-specific Activities of FGF19 Require Klotho beta*
TLDR
KLB is defined as a novel FGFR4 coreceptor required for FGF19 liver specific functions, and is shown to be widely distributed in mouse, whereas KLB distribution is more restricted.
Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases
TLDR
Reduced expression of hepatobiliary transport systems for bile salts and other organic anions may contribute to inflammation‐induced cholestasis in humans and suggests an additional role for posttranscriptional/posttranslational mechanisms.
Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis
  • G. Zollner, M. Wagner, M. Trauner
  • Medicine, Biology
    Liver international : official journal of the International Association for the Study of the Liver
  • 2007
Background: Bile acid synthesis, transport and metabolism are markedly altered in experimental cholestasis. Whether such coordinated regulation exists in human cholestatic diseases is unclear. We
Nuclear receptors. I. Nuclear receptors and bile acid homeostasis.
  • B. Goodwin, S. Kliewer
  • Biology, Medicine
    American journal of physiology. Gastrointestinal and liver physiology
  • 2002
TLDR
A greater understanding of these receptors should afford novel opportunities for therapeutic intervention in chronic diseases such as cholestasis and dyslipidemia.
Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis.
TLDR
The transcriptional regulation of bile acid transporting proteins and metabolizing enzymes mediated by nuclear hormone receptors are illustrated and implications of targeting these receptors for the treatment of cholestasis are discussed.
...
...